Thiopurines, DNA damage, DNA repair and therapy-related cancer

British Medical Bulletin

Volumn 79-80, Issue 1, 2006, Pages 153-170

  Karran, Peter ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

6 Mercaptopurine; 6 Thioguanine; Acute myeloid leukaemia; Azathioprine; DNA mismatch repair; Oxidative DNA damage; Skin cancer; Thiopurines

Indexed keywords

ANTINEOPLASTIC AGENT; PURINE DERIVATIVE;

APOPTOSIS; BASE MISPAIRING; CHEMICALLY INDUCED DISORDER; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; HUMAN; LEUKEMIA; METABOLISM; REVIEW; SECOND CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE PAIR MISMATCH; DNA DAMAGE; DNA REPAIR; HUMANS; LEUKEMIA; NEOPLASMS, SECOND PRIMARY; PURINES;

EID: 34547116188     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldl020     Document Type: Review

References (47)

1. Elion GB (1989) The purine path to chemotherapy. Science, 244, 41-47.
2. Aarbakke J, Janka-Schaub G, Elion GB (1997) Thiopurine biology and pharmacology. Trends Pharmacol Set, 18, 3-8.
3. Warren DJ, Andersen A, Slordal L (1995) Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurme-based maintenance therapy. Cancer Res, 55, 1670-1674.
4. Cuffari C, Li DY, Mahoney J, Barnes JY, Bayless TM (2004) Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-g production in patients with Crohn's disease on AZA therapy. Dig Dis Sci, 49, 133-137.
5. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487-491.
6. Krynetski E, Evans WE (2003) Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene, 22, 7403-7413.
7. Marshall E (2003) Preventing toxicity with a gene test. Science 302, 588-590.
8. Tidd DM, Paterson AR (1974) A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res., 34, 738-746.
9. Bokkerink JPM, Stet EH, dAbreu RA et al. (1993) 6-mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem Pharmacol, 45, 1455-1463.
10. Stet EH, Abreu RAd, Bokkerink JPM et al. (1993) Reversal of 6-mercaptopurine and 6-mercaptopurine ribonucleoside cytotoxicity by amidoimidazole carboxamide ribonucleoside in Molt4 human malignant T-lymphoblasts. Biochem Pharmacol, 46, 547-550.
11. Lennard L, Rees CA, Lilleyman JS, Maddocks JL (1983) Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 16, 359-363.
12. Swann PF, Waters TR, Moulton DC, Xu Y-Z, Edwards M, Mace R (1996) Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science, 273, 1109-1111.
13. Karran P, Offman J, Bignami M (2003) Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie, 85, 1149-1160.
14. Dervieux T, Blanco JG, Krynetski EJ, Vanin EF, Roussel MF, Relling MV (2001) Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res., 61, 5810-5816.
15. Coulthard SA, Hogarth LA, Little M et al. (2002) The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharmacol, 62, 102-109.
16. Macheson EC, Hall AG (2003) Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia. Carcinogenesis, 24, 31-38.
17. Taverna P, Liu L, Hanson AJ, Monks A, Gerson SL (2000) Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol, 46, 507-516.
18. Krynetskaia NF, Brenner TL, Krynetski EY et al. (2003) Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2-/- mice. Mol Pharmacol, 64, 456-465.
19. Yan T, Berry SE, Desai AB, Kinsella TJ (2003) DNA mismatch repair (MMR) mediates 6-thioguanine genocoxicity by introducing single-strand breaks to signal a G2-M arrest in mismatch repair-proficient RKO cells. Clin Cancer Res, 9, 2327-2334.
20. Yamane K, Taylor K, Kinsella TJ (2004) mismatch repair-mediated G2/M arrest by 6-thioguanine involves the ATR-Chk1 pathway. Biochem Biophys Res Commun, 318, 297-302.
21. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms of DNA repair and the DNA damage checkpoints. Ann Rev Biochem, 73, 39-85.
22. 1 type methylating agents requires the ATR kinase. Genes Dev, 18, 1331-1344.
23. Kaplan HS, Smith KC, Tomlin P (1961) Radiosensitization of E. coli by purine and pyrimidine analogues incorporated into deoxyribonucleic acid. Nature, 190, 794-796.
24. Kaplan HS, Zavarine R, Earle J (1962) Interaction of the oxygen effect and radiosensitization produced by base analogues incorporated into deoxyribonucleic acid. Nature, 194, 662-664.
25. Hemmens VJ, Moore DE (1984) Photo-oxidation of 6-mercaptopurine in aqueous solution. Chem Soc Perkin Trans, II, 209-211.
26. Hemmens VJ, Moore DE (1986) Photochemical sensitization by azathioprine and its metabolites-II. Azathioprine and nitroimidazole metabolites. Photochem Photobiol, 43, 257-262.
27. O'Donovan P, Perrett C, Zhang X et al. (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science, 309, 1871-1874.
28. Zhang X, Jeffs G, Ren X et al. (2006) Novel DNA lesions generated by the interaction between therapeutic thiopurines and UVA light. DNA Repair, epublished ahead of print.
29. Azathioprine. (1987) IARC Monographs, Supplement 7, 119.
30. Penn I (1993) Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant, 12, S328-S336.
31. Penn I (2000) Post-transplant malignancy: the role of immunosuppression. Drug Safety, 23, 101-113.
32. Offman J, Opelz G, Doehler B et al. (2004) Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood, 104, 822-828.
33. -/- lymphoblastoid cells to the methylating agent temozolomide. Proc Natl Acad Sci USA, 98, 7164-7169.
34. Molenaar JJ, Gerard B, Chambon-Pautas C et al. (1998) Microsatellite instability and frameshift mutations in BAX and transforming growth factor b RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines. Blood, 92, 230-233.
35. Blanco JG, Dervieux T, Edick MJ et al. (2001) Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastoc leukemia. Proc Natl Acad Sci USA, 98, 10338-10343.
36. Thomsen JB, Schroder H, Kristinsson J et al. (1999) Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells. Cancer, 86, 1080-1086.
37. Larson RS (1997) Microsatellite instability in natural killer cell-like T cell lymphomas in immunocompromised and immunocompetent individuals. Blood, 89, 114-115.
38. Relling MV, Rubnitz JE, Rivera GK et al. (1999) High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet, 354, 34-39.
39. Komeda K, Iwamoto S, Kominami S, Ohnishi T (1997) Induction of cell killing, mutation and umu gene expression by 6-mercaptopurine or 2-thiouracil with UVA irradiation. Photochem Photobiol, 65, 115-118.
40. Purdie KJ, Surentheran T, Sterling JC et al. (2005) Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals. J Invest Dermatol, 125, 98-107.
41. Young AR, Sheehan JM, Chadwick CA, Potten CS (2000) Protection by ultraviolet A and B sunscreens against in situ dipyrimidine photolesions in human epidermis is comparable to protection against sunburn. J Invest Dermatol, 115, 37-41.
42. Liardet S, Scaletta C, Panizzon R, Hohlfeld P, Laurent-Applegate L (2001) Protection against pyrimidine dimers, p53, and 8-hydroxy-2′- deoxyguanosine expression in ultraviolet-irradiated human skin by sunscreens: difference between UVB + UVA and UVB alone sunscreens. J Invest Dermatol, 117, 1437-1441.
43. Berg RJ, Ruven HJ, Sands AT, deGruijl FR, Mullenders LH (1998) Defective global genomic repair in XPC mice is associated with skin cancer susceptibility but not with sensitivity to UVB induced erythema and edema. J Invest Dermatol, 110, 405-409.
44. Lennard L, Thomas S, Harrington CJ, Maddocks JL (1985) Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol, 113, 723-729.
45. Bavinck JNB, Hardie DR, Green A et al. (1996) The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation, 61, 715-721.
46. Remuzzi G, Lesti M, Gotti E et al. (2004) Mycophenolate mofecil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet, 364, 503-512.
47. 6-methylthioguanine. Biochemistry, 36, 2501-2506.